145 related articles for article (PubMed ID: 24082909)
1. Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis.
Yang M; Cen X; Xie Q; Zuo C; Shi G; Yin G
Clin Dev Immunol; 2013; 2013():717808. PubMed ID: 24082909
[TBL] [Abstract][Full Text] [Related]
2. [Levels of acute-phase-reactants in patient with dermatomysitis and its correlations with IL-6 and dermatomyositis disease activity].
Yang M; Liang Y; Cai YF; Lin H; Xie QB; Yin G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):814-7. PubMed ID: 24325119
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.
Yin L; Ge Y; Yang H; Peng Q; Lu X; Zhang Y; Wang G
Clin Rheumatol; 2016 Nov; 35(11):2715-2721. PubMed ID: 27502600
[TBL] [Abstract][Full Text] [Related]
4. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.
He L; Shu X; Liu X; Ge Y; Li S; Lu X; Wang G
Mediators Inflamm; 2020; 2020():6243019. PubMed ID: 32774147
[TBL] [Abstract][Full Text] [Related]
5. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.
Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H
Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523
[TBL] [Abstract][Full Text] [Related]
6. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.
Gabay C; Gay-Croisier F; Roux-Lombard P; Meyer O; Maineti C; Guerne PA; Vischer T; Dayer JM
Arthritis Rheum; 1994 Dec; 37(12):1744-51. PubMed ID: 7986220
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM
Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins.
Lacki JK; Samborski W; Mackiewicz SH
Clin Rheumatol; 1997 May; 16(3):275-8. PubMed ID: 9184265
[TBL] [Abstract][Full Text] [Related]
10. [Significance of v-raf murine sarcoma viral oncogene homologue B1 in rheumatoid arthritis].
Jin YJ; Sun L; Yang L; Xing R; Liu XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):947-950. PubMed ID: 27987495
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease.
Lou Y; Zheng Y; Fan B; Zhang L; Zhu F; Wang X; Chen Z; Tan X; Wei Q
BMC Pulm Med; 2020 Jul; 20(1):196. PubMed ID: 32680574
[TBL] [Abstract][Full Text] [Related]
12. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
Reed AM; Peterson E; Bilgic H; Ytterberg SR; Amin S; Hein MS; Crowson CS; Ernste F; Gillespie EB
Arthritis Rheum; 2012 Dec; 64(12):4078-86. PubMed ID: 22886447
[TBL] [Abstract][Full Text] [Related]
13. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands.
Kang KY; Kim HO; Kwok SK; Ju JH; Park KS; Sun DI; Jhun JY; Oh HJ; Park SH; Kim HY
Arthritis Res Ther; 2011; 13(5):R179. PubMed ID: 22030011
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.
Bentow C; Swart A; Wu J; Seaman A; Manfredi M; Infantino M; Benucci M; Lakos G; Mahler M
Clin Chim Acta; 2013 Sep; 424():141-7. PubMed ID: 23727029
[TBL] [Abstract][Full Text] [Related]
15. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
Lloyd TE; Christopher-Stine L; Pinal-Fernandez I; Tiniakou E; Petri M; Baer A; Danoff SK; Pak K; Casciola-Rosen LA; Mammen AL
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):66-71. PubMed ID: 25892010
[TBL] [Abstract][Full Text] [Related]
16. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels.
Liou LB
Clin Exp Rheumatol; 2003; 21(4):437-44. PubMed ID: 12942694
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of serum myeloperoxidase in patients with active rheumatoid arthritis.
Wang W; Jian Z; Guo J; Ning X
Life Sci; 2014 Nov; 117(1):19-23. PubMed ID: 25261597
[TBL] [Abstract][Full Text] [Related]
18. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].
Chen F; Shu XM; Wang DX; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):204-8. PubMed ID: 22516988
[TBL] [Abstract][Full Text] [Related]
19. Serum level of DNase1l3 in patients with dermatomyositis/polymyositis, systemic lupus erythematosus and rheumatoid arthritis, and its association with disease activity.
Zhao Q; Yang C; Wang J; Li Y; Yang P
Clin Exp Med; 2017 Nov; 17(4):459-465. PubMed ID: 28039554
[TBL] [Abstract][Full Text] [Related]
20. The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients.
Shi Z; Meng Z; Han Y; Cao C; Tan G; Wang L
Lupus; 2018 Apr; 27(4):621-627. PubMed ID: 29058991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
